
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's earnings per share (EPS) estimate for 2025 has been raised to $17.06, reflecting strong second-quarter results and updated guidance, indicating positive financial momentum. The company anticipates a year-over-year increase in earnings for 2027 as margin improvement initiatives take effect, despite the assumption that bonus payments from the Star Ratings program will not recover. Additionally, Humana's above-industry Medicare Advantage star rating profile strengthens its competitive position in the face of regulatory changes, further supporting a favorable long-term outlook.
Bears say
The financial outlook for Humana appears negative, primarily due to management's expectation of a decline in earnings per share (EPS) for 2026 compared to 2025, despite efforts to offset this decrease through margin initiatives. Additionally, various downside risks, including increased competition in Medicare Advantage (MA), inadequate reimbursement rates, and declining Star ratings, could impact profitability and growth, further contributing to a potential EPS shortfall of approximately 10% in FY27. Finally, while management believes there may be a sustained benefit gap against competitors, underlying pressures from the healthcare services sector and challenges in responding to market dynamics remain concerning for the company's future performance.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares